Short talks Pharmacology 12
Cancer pharmacology and treatment

Programme

• 17:30 – 17:42 10 Min. 2 Min.

  • Oral presentation
  • 56

  Mechanisms of drug resistance in chronic myeloid leukemia – The role of cell adhesion signaling and fibronectin 1

  • Meike Kähler (Kiel / DE)

   Cancer pharmacology , Receptor tyrosine kinases
• 17:42 – 17:54 10 Min. 2 Min.

  • Oral presentation
  • 57

  Metabolic inhibition by Devimistat in colorectal cancer treatment: Mechanism of synergy with genotoxic drugs and antimetastatic activity

  • Philipp Demuth (Kaiserslautern / DE)

   Cancer pharmacology , Genotixicity and carcinogenesis
• 17:54 – 18:06 10 Min. 2 Min.

  • Oral presentation
  • 58

  A mutation in the Btk SH2 domain, known to mediate ibrutinib resistance in chronic lymphocytic leukemia, causes a significant increase in kinase function by enhancing its binding affinity to regulatory proteins or peptides

  • Martin Wist (Ulm / DE)

   Cancer pharmacology , Signal transduction and second messengers
• 18:06 – 18:18 10 Min. 2 Min.

  • Oral presentation
  • 59

  Molecular prediction of clinical response to anti-PD-1/anti-PD-L1 immune checkpoint inhibitors: new perspectives for precision medicine and mass spectrometry-based investigations.

  • Margaux Fresnais (Heidelberg / DE)

   Cancer pharmacology , Pharmacogenomics and personalized medicine
• 18:18 – 18:30 10 Min. 2 Min.

  • Oral presentation
  • 88

  Application of Raman spectroscopy for the monitoring of drug delivery and sustained release via porous silicon nanoparticles

  • Elen Tolstik (Dortmund / DE)

   Drug transport/delivery and metabolism, Nanomaterials